Answers are grounded in this paper and cite their sources.
Background Substance use treatment engagement and retention after hospital discharge remain low among patients with nonfatal opioid overdose. It is critical to develop interventions targeting this population due to the persistent opioid overdose crisis. Objective We conducted a single-arm prospective study, the first phase of a 2-phase study (R61/R33, funded by the National Institute on Drug Abuse; DA062351). The objective of the R61 phase was to evaluate the feasibility and acceptability of a 12-week bundled telehealth-enabled intervention aimed at improving treatment engagement and retention among patients with opioid use disorder and a recent nonfatal opioid overdose after hospital discharge. Methods The R61 phase was a single-arm study with no control group. The 12-week comprehensive intervention comprised 4 components, including buprenorphine treatment, telehealth physician visits (weeks 1, 3, 5, 9, and 12 and as needed), telehealth peer service (daily during week 1, every other day during week 2, weekly during weeks 3-12, and as needed), and facilitated linkage to community resources and ongoing treatment. Adults aged 19 years or older with a diagnosis of opioid use disorder and a nonfatal opioid overdose within the previous 12 months were recruited before they were discharged from the University of Alabama at Birmingham Hospital. After enrollment, buprenorphine treatment was initiated or continued, and peer support specialists began engaging and coaching patients. Participants completed validated surveys at baseline and 1 and 3 months. Feasibility will be measured using enrollment and retention rates (benchmark of ≥70% at 3 months). Acceptability will be measured using patient satisfaction and credibility and expectancy scores. Mental health, craving, repeat overdose, and emergency department revisits and readmissions are secondary outcomes. Outcomes will be summarized descriptively. Results The R61 study was funded by the National Institute on Drug Abuse from October 1, 2024, to August 30, 2026. All 30 anticipated participants were enrolled, and 24 completed the intervention. The last participant completed the intervention in April 2026. Data analysis is currently ongoing, and results from the current study are expected to be published in January 2027. Funding for the subsequent R33 phase was awarded in September 2026. Conclusions This study evaluated the feasibility and acceptability of a bundled telehealth-enabled intervention for patients at high risk of repeat overdose and death, a patient population with low treatment uptake and retention after hospital discharge. The findings will inform the upcoming R33 phase, a randomized controlled trial aiming to demonstrate effectiveness in an estimated sample of 160 patients. International Registered Report Identifier (IRRID) DERR1-10.2196/109601
No takes yet. Share an insight, caveat, or question.
Chaparala et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: